U.S. Markets open in 4 hrs 46 mins
  • S&P Futures

    3,775.00
    -46.25 (-1.21%)
     
  • Dow Futures

    30,690.00
    -309.00 (-1.00%)
     
  • Nasdaq Futures

    11,522.00
    -169.00 (-1.45%)
     
  • Russell 2000 Futures

    1,699.00
    -22.40 (-1.30%)
     
  • Crude Oil

    109.80
    +0.02 (+0.02%)
     
  • Gold

    1,815.50
    -2.00 (-0.11%)
     
  • Silver

    20.67
    -0.07 (-0.35%)
     
  • EUR/USD

    1.0454
    +0.0010 (+0.0941%)
     
  • 10-Yr Bond

    3.0930
    0.0000 (0.00%)
     
  • Vix

    29.35
    +0.99 (+3.49%)
     
  • GBP/USD

    1.2152
    +0.0029 (+0.2418%)
     
  • USD/JPY

    136.2810
    -0.2640 (-0.1933%)
     
  • BTC-USD

    19,300.78
    -754.39 (-3.76%)
     
  • CMC Crypto 200

    414.67
    -24.99 (-5.68%)
     
  • FTSE 100

    7,179.87
    -132.45 (-1.81%)
     
  • Nikkei 225

    26,393.04
    -411.56 (-1.54%)
     

BMO Initiates Coverage On This Gene Editing Spearhead

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ: NTLA) with a Market Perform rating and a $54 target price.

  • The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies.

  • But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ: EDIT), and high patient compliance remains.

  • Related: Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer.

  • Although early data suggest that lead asset NTLA-2001 can have a competitive profile in ATTR, penetration will be challenged due to alternative approved/investigational treatments characterized by favorable outcomes and high patient adherence.

  • BMO writes that IND approval for NTLA-2001 can drive ~10-15%+ upside in NTLA.

  • Price Action: NTLA shares are up 4.17% at $43.17 during the market session on the last check Friday.

Latest Ratings for NTLA

Date

Firm

Action

From

To

Mar 2022

Brookline Capital

Upgrades

Hold

Buy

Mar 2022

Chardan Capital

Maintains

Buy

Feb 2022

William Blair

Initiates Coverage On

Outperform

View More Analyst Ratings for NTLA

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.